CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍClinical Trial Agreement • August 6th, 2021
Contract Type FiledAugust 6th, 2021This Clinical Trial Agreement (“Agreement”) dated as of the date of last signature and effective as of the date of publication of this Agreement in the Contract Registry (“Effective Date”) between
ContractClinical Trial Agreement • March 17th, 2021
Contract Type FiledMarch 17th, 2021CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ Protocol # CA209-7DX Protokol číslo CA209-7DX This Clinical Trial Agreement (“Agreement”) dated as of the date of last signature and effective as of the date of publication of this Agreement in the Contract Registry (“Effective Date”) between Tato smlouva o klinickém hodnocení (dále jen„smlouva“) ze dne připojení posledního podpisu s účinností k datu uveřejnění smlouvy v Registru smluv („datum účinnosti“) se uzavírá mezi Syneos Health UK Limited with principal offices located in the United Kingdom at Farnborough Business Park, 1 Pinehurst Road, Farnborough, Hampshire, GU14 7BF, United Kingdom společností Syneos Health UK Limited se sídlem ve Velké Británii na adrese Farnborough Business Park, 1 Pinehurst Road, Farnborough, Hampshire, GU14 7BF, Spojené království and a Masarykův onkologický ústav, with a place of business at Žlutý kopec 7, 656 53 Brno, Czech Republic, ID No.: 00209805, represented by Prof. Marek Svoboda, M